Carbon dioxide laser combined with botulinum toxin A for patients with periorbital syringomas

Seo, Hyun-Min; Choi, Ju-Yeon; Min, Jung; Kim, Won‐Serk

doi:10.3109/14764172.2015.1052517

Cited by 20 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BTXA is a neurotoxic protein and effective in the treatment of several disorders [16–18]. In recent decade, BTXA has been recommended to treat keloid and achieved promising results [19].…”

Section: Discussionmentioning

confidence: 99%

BTXA regulates the epithelial–mesenchymal transition and autophagy of keloid fibroblasts via modulating miR-1587/miR-2392 targeted ZEB2

2019

View full text Add to dashboard Cite

Keloids are very resistant to treatment in dermatology and plastic surgical practice. The present study aimed to explore the underlying mechanism of botulinum toxin A (BTXA) treated human skin keloid fibroblasts (HSFBs) proving some new insights into keloids treatment. Expression of miR-1587 and miR-2392 were significantly down-regulated in keloid tissues and HSFBs, while the ZEB2 was a target of both and up-regulated in keloid tissues and HSFBs compared with the normal controls. BTXA could significantly increase the expression of miR-1587 and miR-2392 but decrease the expression of ZEB2. BTXA could significantly inhibit the proliferation, cell cycle, and migration and promote apoptosis and autophagy of HSFBs; however, miR-1587 and miR-2392 inhibitors could reverse these effects of BTXA on HSFBs. Silencing ZEB2 could significantly attenuate the effects of miR-1587 and miR-2392 inhibitors in promoting cell proliferation and migration and suppressing apoptosis and autophagy of HSFBs after treating with BTXA. BTXA could suppress the proliferation and migration and promote apoptosis and autophagy of HSFBs via modulating miR-1587/miR-2392 targeted ZEB2.

show abstract

Section: Discussionmentioning

confidence: 99%

BTXA regulates the epithelial–mesenchymal transition and autophagy of keloid fibroblasts via modulating miR-1587/miR-2392 targeted ZEB2

2019

View full text Add to dashboard Cite

show abstract

“…While AFLs and especially NAFLs have decreased these risks, caution is still advised when using these devices. The potential for laser‐induced erythema, edema, scabbing, blistering, scarring, and pigmentary changes still exists with LADD, especially at higher fluences and treatment densities . Thus, when deciding which laser system to use, the practitioner must not only consider how to achieve the desired effects, but also be aware of potential side effects associated with general laser use as well as challenges to patient tolerability, including patient skin type and anatomical treatment area.…”

Section: Introductionmentioning

confidence: 99%

Challenges to laser‐assisted drug delivery: Applying theory to clinical practice

et al. 2017

View full text Add to dashboard Cite

Background The percutaneous penetration of topically applied compounds can be enhanced using external chemical or physical sources and thus laser‐assisted drug delivery is a burgeoning area of interest within the field of dermatology. Objectives This article briefly discusses the mechanism of laser‐assisted drug delivery and expands upon the challenges and safety issues that may arise in the clinical implementation of this modality. Results The existing literature demonstrates that investigators and clinicians in dermatology have successfully delivered anti‐inflammatory, anti‐neoplastic, and anti‐oxidative medications transdermally for the treatment of a variety of conditions including scarring, photoageing, and cutaneous neoplasia. Despite growth of the field, much remains to be learned about the applicability of laser‐assisted drug delivery in humans, and practitioners are faced with new safety concerns that may be associated with this treatment modality. Conclusions Challenges in laser assisted drug delivery include unpredictability of dosing and response to therapy, possibility of inducing local and systemic reactions, and variability in treatment regimens. Lasers Surg. Med. 50:20–27, 2018. © 2017 Wiley Periodicals, Inc.

show abstract

“…Periorbital syringomas are commonly treated with CO2 laser. However, the combined approach with onabotulinumtoxinA has been found to give better results in 48 patients, as compared to 44 subjects treated with CO2 only [ 55 ].…”

Section: Resultsmentioning

confidence: 99%

New trends in botulinum toxin use in dermatology

Guida¹,

Farnetani²,

Nisticò³

et al. 2018

Dermatol Pract Concept

View full text Add to dashboard Cite

BackgroundRecent studies have highlighted new botulinum neurotoxin (BoNT) applications in the field of dermatology.ObjectiveTo review current knowledge of BoNT use in dermatology.MethodsThe literature of the last 5 five years has been reviewed.ResultsWe describe interesting protocols of BoNT treatment for hyperhidrosis (HH), hypertrophic scars and keloids, Raynaud phenomenon, facial flushing, oily skin, psoriasis, Hailey-Hailey disease, and cutaneous lesions like painful lesions and periorbital syringomas.ConclusionsSeveral skin conditions eligible for BoNT treatment have been described. After the wide application for HH treatment, scars as well as vascular and inflammatory skin disorders, oily skin and cutaneous lesions represent fields of application of BoNT.

show abstract

Carbon dioxide laser combined with botulinum toxin A for patients with periorbital syringomas

Abstract: CO2 laser combined with BTXA showed better effect than CO2 laser only.

Cited by 20 publications

References 18 publications

BTXA regulates the epithelial–mesenchymal transition and autophagy of keloid fibroblasts via modulating miR-1587/miR-2392 targeted ZEB2

BTXA regulates the epithelial–mesenchymal transition and autophagy of keloid fibroblasts via modulating miR-1587/miR-2392 targeted ZEB2

Challenges to laser‐assisted drug delivery: Applying theory to clinical practice

New trends in botulinum toxin use in dermatology

Contact Info

Product

Resources

About